OBJECTIVES: To compare patient characteristics and drug utilization among CHC patients with and without CKD in a US treated CHC population. METHODS: De-identified, individual-level healthcare claims data from Truven Health MarketScan® database was analyzed. CHC was defined as those who had ≥2 medical claims of HCV (ICD9: 070.54, 070.44, 070.70, 070.71) ≥ 1 month apart. Three-year continuous enrollment was required in order to capture prior treatment experience. The CHC treated cohort was defined as those who had at least 1 HCV medication prescribed between July 2013 and June 2014.   RESULTS: Of 2,558 CHC treated patients, 142 patients (5.6%) were identified as having CKD . The mean age of CHC patients with CKD  was 61 years compared to 57 years among those without CKD (p<.0001). Compared to  CHC patients without CKD (n = 2,416), patients with CKD had significantly more comorbidities including diabetes (53% vs 23%, p<.0001), major depression (15% vs.6%, p=.0007), hypertension (85% vs. 51%, p<.0001) and heart failure (19% vs. 2%, p<.0001). CHC patients with CKD also had higher prevalence of kidney transplants (11% vs.1%, p<.0001) and more liver transplants (35% vs. 6%, p<.0001).  For concomitant drug use, CHC patients with CKD had significantly more concomitant drugs (by drug class) during the 2-year baseline period compared to those without CKD (17 vs 11, p<.0001). Average annual out-of-pocket pharmacy expenses at baseline were significantly higher among CHC patients with CKD compared to those without CKD ($1,079 vs. $606, p<.0001). CONCLUSIONS: In a US commercially insured population, treated CHC patients with CKD had significantly higher rates of comorbidities and drug utilization compared to those without CKD.